Close

Orphazyme A/S (ORPH) falls as trial of arimoclomol for Inclusion Body Myositis fails to met Primary and Secondary Endpoints

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 4/25/2024

1. META
2. CMG
3. LRCX
4. IBM
5. SPY
6. BA
7. HCP
8. SNAP
9. TMUS
10. BSX


Go back to Orphazyme A/S (ORPH) falls as trial of arimoclomol for Inclusion Body Myositis fails to met Primary and Secondary Endpoints
(NASDAQ: ORPH) Delayed: 0.87 --0 (-0%)
Previous Close $0.87    52 Week High $ 
Open $0.87    52 Week Low $ 
Day High $0.87    P/E N/A 
Day Low $0.87    EPS $ 
Volume 215,980